Fig. 2

The efficacy of PTX is altered when ALDH2 is regulated by drug or genetic intervention in NSCLC cells. A MTT assay results showing the efficacy of PTX in NSCLC/PTX cells transfected with ALDH2 shRNA or scramble for 72 h. ^*p < 0.05, ^**p < 0.01, as compared to the scramble group. B MTT assay results showing the efficacy of PTX in NSCLC cells transfected with ALDH2 overexpression (OE) or empty plasmid for 72 h. ^*p < 0.05, ^**p < 0.01, as compared to the empty group. C Colony formation assay and Transwell migration assay in NCI-H460/PTX cells transfected with ALDH2 shRNA or scramble. The photographs were taken at magnifications of × 200. Scale bar = 50 μm. D Colony formation assay and Transwell migration assay in NCI-H460 cells transfected with ALDH2 overexpression (OE) or empty plasmid. The photographs were taken at magnifications of × 200. Scale bar = 50 μm. E MTT assay results showing the efficacy of PTX in NSCLC/PTX cells treated with DZN (10 μM) or vehicle for 72 h. ^*p < 0.05, ^**p < 0.01, as compared to the PTX group. F MTT assay results showing the efficacy of PTX in NSCLC/PTX cells transfected with siRNAs against specific ALDH subtypes or control siRNA for 72 h. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, as compared to the scramble group. G The number of metastases from NSCLC cells transfected with ALDH2 overexpression (OE) or empty plasmid in lung, brain and bone. H Top: Schematic view of the establishment and treatment of NCI-H1299 xenograft mice. NCI-H1299 cells were injected into the right flank of BALB/c nude mice. PTX was administered as indicated by colored triangles (i.p., intraperitoneal). Bottom: Bioluminescence images showing tumor growth in NCI-H1299 xenograft mice treated with PTX or vehicle. ^**p < 0.01, ^***p < 0.001, as compared to the empty group, ^###p < 0.001, as compared to the ALDH2 overexpression group